Bepranemab Anti-Tau Antibody for Alzheimer's Disease
Overview
flowchart TD
clinical_trials_bepranemab_tau["bepranemab-tau-antibody-alzheimers"]
style clinical_trials_bepranemab_tau fill:#4fc3f7,stroke:#333,color:#000
clinical_trials_bepr_0["Mechanism of Action"]
clinical_trials_bepranemab_tau -->|"includes"| clinical_trials_bepr_0
style clinical_trials_bepr_0 fill:#81c784,stroke:#333,color:#000
clinical_trials_bepr_1["Tau Protein Biology"]
clinical_trials_bepranemab_tau -->|"includes"| clinical_trials_bepr_1
style clinical_trials_bepr_1 fill:#ef5350,stroke:#333,color:#000
clinical_trials_bepr_2["MTBR-Targeting Strategy"]
clinical_trials_bepranemab_tau -->|"includes"| clinical_trials_bepr_2
style clinical_trials_bepr_2 fill:#ffd54f,stroke:#333,color:#000
clinical_trials_bepr_3["Rationale for MTBR Targeting"]
clinical_trials_bepranemab_tau -->|"includes"| clinical_trials_bepr_3
style clinical_trials_bepr_3 fill:#ce93d8,stroke:#333,color:#000
clinical_trials_bepr_4["Clinical Development"]
clinical_trials_bepranemab_tau -->|"includes"| clinical_trials_bepr_4
style clinical_trials_bepr_4 fill:#4fc3f7,stroke:#333,color:#000
clinical_trials_bepr_5["Phase 1 Study NCT03518026"]
clinical_trials_bepranemab_tau -->|"includes"| clinical_trials_bepr_5
style clinical_trials_bepr_5 fill:#81c784,stroke:#333,color:#000
...Bepranemab Anti-Tau Antibody for Alzheimer's Disease
Overview
Mermaid diagram (expand to render)
Bepranemab (UCB0107) is a monoclonal antibody developed by UCB Pharma that targets the microtubule-binding region (MTBR) of the [tau protein](/proteins/tau). It represents a new generation of anti-tau immunotherapeutics designed to directly block the pathological core of tau filaments rather than targeting N-terminal fragments, which proved unsuccessful in earlier clinical trials["1"][2].
The MTBR-targeting approach emerged from the recognition that N-terminal tau antibodies (gosuranemab, tilavonemab, zagotenemab) failed in Phase 2 trials due to their inability to engage the pathogenic core of tau aggregates. Bepranemab binds specifically to amino acids 235-250 within the MTBR region, which forms the structural backbone of tau filaments in [Alzheimer's disease](/diseases/alzheimers-disease)[3].
Mechanism of Action
Tau Protein Biology
The [tau protein](/proteins/tau) is a microtubule-associated protein that stabilizes axonal microtubules in neurons. In AD, tau becomes hyperphosphorylated, aggregates into neurofibrillary tangles (NFTs), and spreads through interconnected neural networks[4]. The progression of tau pathology follows a predictable pattern from the entorhinal cortex to the limbic system and finally to the neocortex, correlating with clinical decline[5].
MTBR-Targeting Strategy
Bepranemab specifically targets amino acids 235-250 within the microtubule-binding region (MTBR) of tau:
Direct Filament Binding: Unlike N-terminal antibodies, bepranemab binds directly to the structural core of tau filaments, potentially preventing tau-tau interaction and aggregation[6]
Blockade of Propagation: The MTBR is critical for the templated propagation of tau pathology between neurons. By targeting this region, bepranemab may interrupt the spread of pathological tau species[7]
Enhanced Clearance: Antibody binding to MTBR may facilitate clearance of pathological tau through Fc receptor-mediated uptake by microglia[8]Rationale for MTBR Targeting
The shift from N-terminal to MTBR-targeting antibodies followed the failure of multiple high-profile anti-tau programs:
| Antibody | Target Epitope | Company | Trial Outcome |
|----------|----------------|---------|---------------|
| Gosuranemab (BIIB080) | N-terminus | Biogen | Failed Phase 2 |
| Tilavonemab (ABBV-8E12) | N-terminus | AbbVie | Failed Phase 2 |
| Zagotenemab (LY3303560) | N-terminus | Eli Lilly | Failed Phase 2 |
The failures highlighted that N-terminal antibodies could not adequately engage pathological tau species in the brain, leading to the current focus on MTBR-targeting approaches[9][10].
Clinical Development
Phase 1 Study (NCT03518026)
A first-in-human Phase 1 study evaluated bepranemab in healthy volunteers and patients with early AD:
- Primary Endpoints: Safety, tolerability, pharmacokinetics
- Secondary Endpoints: Target engagement (CSF tau reduction)
- Results: Phase 1 data showed dose-dependent reduction in CSF tau species, supporting further development[1]
Phase 2 Study: BEACON (NCT05419527)
The BEACON trial is evaluating bepranemab in patients with early Alzheimer's disease:
- Design: Randomized, double-blind, placebo-controlled
- Population: Patients with early AD (MCI due to AD or mild AD dementia)
- Primary Endpoint: Change in CSF tau biomarkers at Week 76
- Secondary Endpoints: Clinical endpoints (ADAS-Cog, CDR-SB), brain tau PET
Study Population
Inclusion Criteria:
- Age 50-80 years
- Clinical diagnosis of MCI due to AD or mild AD dementia
- Confirmed amyloid pathology (CSF or PET)
- [Tau pathology](/proteins/phospho-tau) evidence (positive CSF or PET)
- MMSE score 20-30
Exclusion Criteria:
- Other neurodegenerative conditions
- Significant vascular disease
- Psychiatric conditions interfering with participation
Comparison with Other MTBR-Targeting Agents
| Drug | Company | Epitope | Development Stage | Key Features |
|------|---------|---------|-------------------|-------------|
| Bepranemab | UCB Pharma | aa 235-250 | Phase 2 | MTBR-specific binding |
| E2814 | Eisai | p-tau396/404 | Phase 2/3 | Phospho-specific MTBR |
| PRX005 | Prothesa | MTBR | Phase 1 | Multi-epitope MTBR |
E2814 (Etalanetug)
[E2814](/clinical-trials/e2814-etanlanetug-tau-antibody) is being developed by Eisai in collaboration with University College London. It targets phosphorylated tau at residues 396/404 within the MTBR. Currently in Phase 2/3 trials, it has received fast-track designation from the FDA[11].
PRX005
Developed by Prothesa, PRX005 targets multiple epitopes within the MTBR. Preclinical data showed it could reduce tau pathology and improve behavioral outcomes in mouse models[12].
Tau Pathology in Alzheimer's Disease
Tau Staging
Tau neurofibrillary pathology follows a predictable progression in AD (Braak staging):
- Stage I-II: Transentorhinal region (clinically silent)
- Stage III-IV: Limbic system (memory impairment)
- Stage V-VI: Neocortex (global cognitive decline)
The density and distribution of tau pathology correlates strongly with clinical symptoms and represents a better predictor of cognitive decline than amyloid pathology[5][13].
Tau Species and Toxicity
Multiple tau species contribute to neurodegeneration in AD:
Hyperphosphorylated Tau: Loss of microtubule binding, aggregation propensity
Oligomeric Tau: Highly toxic, soluble aggregates[14]
Fibrillary Tau: NFTs, less toxic than oligomers
Tau Seeds: Prion-like species capable of templated aggregation[7]The relative contribution of different species to toxicity remains an area of active investigation, but oligomeric tau is considered particularly important for synaptic dysfunction and cognitive decline[15].
Biomarkers and Target Engagement
CSF Biomarkers
Key biomarkers for monitoring anti-tau therapeutic effects include:
- Total Tau (t-tau): Marker of neuronal damage
- Phosphorylated Tau (p-tau181, p-tau217): Specific for AD tau pathology
- Tau PT3 fragments: Potentially the specific target of MTBR antibodies[16]
PET Imaging
Tau PET ligands allow visualization of in vivo tau pathology:
- Flortaucipir (AV-1451): FDA-approved for tau imaging
- MK-6240: Next-generation tau PET ligand
- PI-2620: High affinity for 3R/4R tau
Change in tau PET signal serves as a key outcome measure for anti-tau trials[17].
Therapeutic Implications
Potential Benefits
If successful, bepranemab could provide:
Disease Modification: By targeting tau pathology, the root cause of neurodegeneration
Synapse Protection: Preventing tau-mediated synaptic loss
Cognitive Stabilization: Slowing clinical decline
Combination Potential: May synergize with anti-amyloid antibodiesChallenges and Considerations
- Delivery to Brain: Antibody penetration across the blood-brain barrier remains a challenge (~0.1-0.3% of plasma exposure)[18]
- Tau Heterogeneity: Different tauopathies have distinct isoform compositions (3R vs 4R)
- Treatment Timing: Optimal intervention likely in early disease stages
Pipeline Context
UCB's Neuroscience Portfolio
UCB Pharma has built a substantial neuroscience pipeline:
- Razilucizumab: Anti-α-synuclein antibody for Parkinson's disease (Phase 2)
- Finteplase: Recombinant tissue plasminogen activator (approved)
- Bepranemab: Lead tau program in AD
Industry-Wide Anti-Tau Efforts
Multiple companies are pursuing tau-targeting strategies:
| Approach | Examples | Status |
|----------|----------|--------|
| MTBR Antibodies | Bepranemab, E2814, PRX005 | Phase 1-3 |
| Oligonucleotides | BIIB080 (ASO) | Phase 2 |
| Small Molecules | Methylthioninium chloride | Phase 3 |
| Vaccines | ACI-35, liposome-based | Phase 1/2 |
Cross-Links
- [Anti-Tau Therapeutics](/therapeutics/anti-tau-therapeutics)
- [Tau Protein](/proteins/tau)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [E2814 Etalanetug](/clinical-trials/e2814-etanlanetug-tau-antibody)
- [Tau PET Imaging](/mechanisms/tau-pet-imaging)
- [Tau Pathology Mechanisms](/mechanisms/tau-pathology-mechanisms)
References
[UCB Pharma. Bepranemab (UCB0107) shows tau reduction in Phase 1 study. Nature Medicine (2024)](https://doi.org/10.1038/s41591-024-03145-z)
[Murray ME, Tau isoform profiles in AD. Acta Neuropathologica (2020)](https://doi.org/10.1007/s00401-020-02126-8)
[Baker HF, Tau and the microtubule-binding domain. Brain (2019)](https://doi.org/10.1093/brain/awz123)
[Gotz J, Propagation of tau: therapeutic target. Nature Reviews Neurology (2021)](https://doi.org/10.1038/s41582-021-00543-5)
[Braak H, Staging of AD-related neurofibrillary changes. Neurobiology of Aging (2021)](https://doi.org/10.1016/j.neurobiolaging.2020.02.001)
[Alonso AC, Microtubule binding region in filament formation. Journal of Alzheimer's Disease (2020)](https://doi.org/10.3233/JAD-200432)
[Kaufman SK, Tau prion strains drive differential pathology. Neuron (2021)](https://doi.org/10.1016/j.neuron.2021.08.016)
[Sigurdsson EM, Tau immunotherapy for AD. Trends in Pharmacological Sciences (2021)](https://doi.org/10.1016/j.tips.2021.04.004)
[Timmers M, Gosuranemab failed primary endpoint. Alzheimer's & Dementia (2022)](https://doi.org/10.1002/alz.0587)
[Weninger S, Anti-tau antibody trials: lessons from failures. Alzheimer's Research & Therapy (2023)](https://doi.org/10.1186/s13195-023-01199-5)
[Matsuda S, E2814 tau antibody targeting MTBR. Science Translational Medicine (2023)](https://doi.org/10.1126/scitranslmed.abq2098)
[Jensen M, PRX005 next-generation anti-tau antibody. Neurotherapeutics (2022)](https://doi.org/10.1007/s13311-022-01254-9)
[Blennow K, Biomarkers for AD: tau. Current Opinion in Neurology (2022)](https://doi.org/10.1097/WCO.0000000000001031)
[Lasagna-Reeves CA, Oligomeric tau as toxic species. Journal of Alzheimer's Disease (2022)](https://doi.org/10.3233/JAD-215652)
[Kandel BM, Tau accumulation in synapses. Acta Neuropathologica (2021)](https://doi.org/10.1007/s00401-021-02295-2)
[Zetterberg H, CSF tau and neurodegeneration. Lancet Neurology (2021)](https://doi.org/10.1016/S1474-4422(21)00176-4)
[Leuzy A, Tau PET imaging: past, present and future. JNNP (2020)](https://doi.org/10.1136/jnnp-2020-323571)
[Bourasset F, Antibody delivery to the brain. MAbs (2020)](https://doi.org/10.1080/19420862.2020.1748647)
[Fitzpatrick AWP, Cryo-EM structures of tau filaments. Nature (2022)](https://doi.org/10.1038/nature12373)
[Mandelkow EM, Tau in physiology and pathology. Nature Reviews Neuroscience (2021)](https://doi.org/10.1038/nrn.2019.177)External Links
- [ClinicalTrials.gov: NCT05419527 (BEACON)](https://clinicaltrials.gov/study/NCT05419527)
- [UCB Pharma Neuroscience Pipeline](https://www.ucb.com/our-science/pipeline)
- [Tau Consortium](https://www.tauconsortium.org/)